Announcements Trials

Browse Landscape

Phase

Status

Completed 25 Terminated 10 Withdrawn 1 Unknown 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 15 Other hematologic neoplasm 12 CNS 9 Genitourinary 8 Plasma cell 7 Breast 7 Myeloid 4 Thoracic 3 Gynecologic 3 Sarcoma 1 Other solid neoplasm 1 Head & Neck 1 Gastrointestinal 1 Dermatologic 1 Classical hematology 1

Conditions

Interventions

Nivolumab 25 pembrolizumab 21 Ipilimumab 15 Temozolomide 13 toripalimab 12 Biopsy 10 Imiquimod 8 Cyclophosphamide 8 Dacarbazine 7 Blood Specimen Collection 7 camrelizumab 6 Chemotherapy, Adjuvant 6 trametinib 5 dabrafenib 5 atezolizumab 5 aldesleukin 5 Gene Expression Profiling 5 Cisplatin 5 Aminolevulinic Acid 5 fludarabine phosphate 4 fludarabine 4 durvalumab 4 binimetinib 4 apatinib 4 Tomography, Optical Coherence 4 Sorafenib 4 Photochemotherapy 4 Injections 4 Bevacizumab 4 tislelizumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Filgrastim × Dermatologic × Clear all

NCT00017355 2013-09-17

Vaccine Therapy in Treating Patients With Metastatic Melanoma

National Cancer Institute (NCI)

Phase 1 Unknown

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡